Tirzepatide: Mechanism of Action
Mechanism of Action
Primary Target: The GLP-2 Receptor (GLP-2R)
Teduglutide acts as a full agonist at the GLP-2 receptor, a class B (secretin-family) Gαs-coupled GPCR expressed predominantly on intestinal sub-epithelial myofibroblasts, enteric neurons, and a subset of enteroendocrine cells. Receptor occupancy elevates intracellular cAMP and triggers downstream protein-kinase-A signaling, which has been mapped in primary cell and explant studies to (a) release of insulin-like growth factor-1 (IGF-1) from sub-epithelial fibroblasts, (b) release of keratinocyte growth factor (KGF), and (c) modulation of vasoactive intestinal peptide (VIP) and nitric oxide tone in enteric neurons.[2][7]
DPP-IV Resistance and Pharmacokinetic Profile
The Ala²Gly substitution that defines teduglutide eliminates the canonical DPP-IV cleavage site at the N-terminal His-Ala dipeptide. In rodent pharmacokinetic studies, the in-vivo half-life of teduglutide is ~2 hours after subcutaneous administration, compared with ~7 minutes for native GLP-2. This extended exposure window allowed investigators to study sustained GLP-2R activation in chronic dosing models — a regime that is mechanistically inaccessible with native peptide because of rapid enzymatic degradation.[1][8]
Indirect Trophic Cascade — Cellular Cross-Talk
A central mechanistic finding from the GLP-2R research literature is that the receptor is not expressed on the intestinal stem cells or enterocytes whose proliferation increases. Instead, GLP-2R activation on sub-epithelial fibroblasts and enteric neurons triggers paracrine release of IGF-1 and KGF, which act on stem-cell and transit-amplifying compartments in the crypt. IGF-1-receptor knockout mice show abolished intestinotrophic response to teduglutide, providing a clean genetic dissection of the mechanism.[7]
Mucosal Growth Endpoints in Preclinical Models
| Endpoint | Direction | Model Context |
|---|---|---|
| Small-bowel mass | Increased | Rodent intestinal-resection and parenteral-nutrition models[3] |
| Villus height | Increased | Histomorphometric analysis of jejunal mucosa[4] |
| Crypt depth | Increased | BrdU labeling of crypt proliferative compartment[7] |
| Enterocyte apoptosis | Decreased | TUNEL staining in colitis and ischemia models[9] |
| Tight-junction protein expression | Increased | ZO-1 / occludin Western blot in barrier-permeability models[9] |
Receptor Selectivity
Teduglutide exhibits high selectivity for the GLP-2R; binding studies show no measurable cross-reactivity with the GLP-1, GIP, glucagon, or secretin receptors at concentrations relevant to GLP-2R activation, supplying investigators with a clean GLP-2R-selective probe within the proglucagon-derived peptide family.[2]
“Preclinical Research Summary Foundational Studies StudyModelKey FindingsRef Drucker et al.”
References
- Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA. 1996;93(15):7911-7916.
- Drucker DJ, Shi Q, Crivici A, et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol. 1997;15(7):673-677.
- Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol. 1998;275(5):G911-G921.
- Cheeseman CI, Tsang R. The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport. Am J Physiol. 1996;271(3):G477-G482.
- Munroe DG, Gupta AK, Kooshesh F, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA. 1999;96(4):1569-1573.
- Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014;76:561-583.
- Dubé PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology. 2006;131(2):589-605.
- Marier JF, Beliveau M, Mouksassi MS, et al. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol. 2008;48(11):1289-1299.
- Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol. 1999;277(5):E937-E947.
- Burrin DG, Stoll B, Guan X, et al. Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology. 2005;146(1):22-32.
- Prasad R, Alavi K, Schwartz MZ. Glucagon-like peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. J Pediatr Surg. 2000;35(2):357-359.
- Yusta B, Holland D, Koehler JA, et al. ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology. 2009;137(3):986-996.
Related Research Questions
Want the complete research review?
View Full Tirzepatide Research Page→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.